Видео ютуба по тегу Triple-Class Exposed

Managing patients with triple-class exposed myeloma using combination therapies
Managing patients with triple-class exposed myeloma using combination therapies
What are the major advances for the triple-class exposed population?
What are the major advances for the triple-class exposed population?
Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma
Efficacy of Teclistimab versus current treatments in patients with triple-class exposed RR myeloma
Hans Lee, MD, Covers Outcomes, Treatments After Triple-Class Exposure in Myeloma
Hans Lee, MD, Covers Outcomes, Treatments After Triple-Class Exposure in Myeloma
Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?
Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?
Real-world treatment patterns & outcomes among patients with triple-class exposed myeloma
Real-world treatment patterns & outcomes among patients with triple-class exposed myeloma
The promise of CAR-T cells for patients with triple-class exposed myeloma
The promise of CAR-T cells for patients with triple-class exposed myeloma
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
KarMMa-3 results: ide-cel vs standard regimens in triple-class exposed multiple myeloma
Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma
Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma
KarMMa-3 trial updates: ide-cel versus SOC in triple-class exposed R/R multiple myeloma
KarMMa-3 trial updates: ide-cel versus SOC in triple-class exposed R/R multiple myeloma
Cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
Cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma
Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma
ASH23: KarMMa-3 Study: Ide-Cel for Triple-Class-Exposed RRMM Patients | Paula Rodriguez Otero, MD
ASH23: KarMMa-3 Study: Ide-Cel for Triple-Class-Exposed RRMM Patients | Paula Rodriguez Otero, MD
Ciltacabtagene Autoleucel in CARTITUDE-1 Vs Standard of Care in Triple-Class Exposed MM pts
Ciltacabtagene Autoleucel in CARTITUDE-1 Vs Standard of Care in Triple-Class Exposed MM pts
The benefit of bispecific antibodies & CAR-T therapy in triple class-exposed multiple myeloma
The benefit of bispecific antibodies & CAR-T therapy in triple class-exposed multiple myeloma
Comparing elranatamab with real-world therapies in triple-class-refractory myeloma
Comparing elranatamab with real-world therapies in triple-class-refractory myeloma
Real world data supports ciltacabtagene autoleucel as a effective option for triple-class expose...
Real world data supports ciltacabtagene autoleucel as a effective option for triple-class expose...
Approval of teclistamab in triple-class refractory multiple myeloma
Approval of teclistamab in triple-class refractory multiple myeloma